| Stockholders' Equity |
Series A Preferred Stock
Mr. Solomita’s amended employment agreement
of February 15, 2016 provides that the Company shall issue to Mr. Solomita one share of the Company’s Series A Preferred
Stock in exchange for Mr. Solomita agreeing not to terminate his employment with the Company for a period of five years from the
date of the agreement. The agreement effectively provides Mr. Solomita with a “change of control” provision over the
Company in the event that his ownership of the issued and outstanding shares of common stock of the Company is diluted to less
than a majority. In order to issue Mr. Solomita his one share of Series A Preferred Stock under the amendment, the Company created
a “blank check” preferred stock. Subsequently, the board of directors of the Company approved a Certificate of Designation
creating the Series A Preferred Stock. Subsequently, the Company issued one share of Series A Preferred Stock to Mr. Solomita.
The one share of Series A Preferred Stock issued
to Mr. Solomita holds a majority of the total voting power so long as Mr. Solomita holds not less than 7.5% of the
issued and outstanding shares of common stock of the Company, assuring Mr. Solomita of control of the Company in the event that
his ownership of the issued and outstanding shares of common stock of the Company is diluted to a level below a majority. Currently,
Mr. Solomita’s ownership of 19,010,000 shares of common stock and 1 share of Series A Preferred Stock provides him with 77.0%
of the voting control of the Company.
Additionally, the one share of Series A Preferred
Stock issued to Mr. Solomita contains protective provisions, which precludes the Company from taking certain actions without Mr.
Solomita’s (or that of any person to whom the one share of Series A Preferred Stock is transferred) approval. More specifically,
so long as any shares of Series A Preferred Stock are outstanding, the Company shall not, without first obtaining the approval
(by vote or written consent, as provided by law) of the holders of at least a majority of the then outstanding shares of Series
A Preferred Stock, voting as a separate class:
| (a) |
amend the Articles of Incorporation or, unless approved by the Board of Directors, including by the Series A Director, amend the Company’s By-laws; |
| (b) |
change or modify the rights, preferences or other terms of the Series A Preferred Stock, or increase or decrease the number of authorized shares of Series A Preferred Stock; |
| (c) |
reclassify or recapitalize any outstanding equity securities, or, unless approved by the Board of Directors, including by the Series A Director, authorize or issue, or undertake an obligation to authorize or issue, any equity securities or any debt securities convertible into or exercisable for any equity securities (other than the issuance of stock-options or securities under any employee option or benefit plan); |
| (d) |
authorize or effect any transaction constituting a Deemed Liquidation (as defined in this subparagraph) under the Articles, or any other merger or consolidation of the Company; |
| (e) |
increase or decrease the size of the Board of Directors as provided in the By-laws of the Company or remove the Series A Director (unless approved by the Board of Directors, including the Series A Director); |
| (f) |
declare or pay any dividends or make any other distribution with respect to any class or series of capital stock (unless approved by the Board of Directors, including the Series A Director); |
| (g) |
redeem, repurchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any outstanding shares of capital stock (other than the repurchase of shares of common stock from employees, consultants or other service providers pursuant to agreements approved by the Board of Directors under which the Company has the option to repurchase such shares at no greater than original cost upon the occurrence of certain events, such as the termination of employment) (unless approved by the Board of Directors, including the Series A Director); |
| (h) |
create or amend any stock option plan of the Company, if any (other than amendments that do not require approval of the stockholders under the terms of the plan or applicable law) or approve any new equity incentive plan; |
| (i) |
replace the President and/or Chief Executive Officer of the Company (unless approved by the Board of Directors, including the Series A Director); |
| (j) |
transfer assets to any subsidiary or other affiliated entity (unless approved by the Board of Directors, including the Series A Director); |
| (k) |
issue, or cause any subsidiary of the Company to issue, any indebtedness or debt security, other than trade accounts payable and/or letters of credit, performance bonds or other similar credit support incurred in the ordinary course of business, or amend, renew, increase or otherwise alter in any material respect the terms of any indebtedness previously approved or required to be approved by the holders of the Series A Preferred Stock (unless approved by the Board of Directors, including the Series A Director); |
| (l) |
modify or change the nature of the Company’s business; |
| (m) |
acquire, or cause a Subsidiary of the Company to acquire, in any transaction or series of related transactions, the stock or any material assets of another person, or enter into any joint venture with any other person (unless approved by the Board of Directors, including the Series A Director); or |
| (n) |
sell, transfer, license, lease or otherwise dispose of, in any transaction or series of related transactions, any material assets of the Company or any Subsidiary outside the ordinary course of business (unless approved by the Board of Directors, including the Series A Director). |
Common Stock
| For the year ended February 28, 2021 |
|
Number of shares |
|
|
Amount |
|
| Balance, February 29, 2020 |
|
|
39,910,774 |
|
|
$ |
3,992 |
|
| Issuance of shares for cash |
|
|
2,087,000 |
|
|
|
209 |
|
| Issuance of shares upon the exercise of warrants |
|
|
190,529 |
|
|
|
19 |
|
| Issuance of shares upon settlement of restricted stock units |
|
|
225,388 |
|
|
|
22 |
|
| Balance, February 28, 2021 |
|
|
42,412,739 |
|
|
$ |
4,242 |
|
| For the year ended February 29, 2020 |
|
Number of shares |
|
|
Amount |
|
| Balance, February 28, 2019 |
|
|
33,805,706 |
|
|
$ |
3,381 |
|
| Issuance of shares for cash |
|
|
4,693,567 |
|
|
|
469 |
|
| Issuance of shares upon vesting of restricted stock units |
|
|
244,884 |
|
|
|
25 |
|
| Issuance of shares upon the cashless exercise of stock options |
|
|
69,101 |
|
|
|
7 |
|
| Issuance of shares upon the exercise of warrants |
|
|
15,432 |
|
|
|
1 |
|
| Issuance of shares upon settlement of legal matter |
|
|
150,000 |
|
|
|
15 |
|
| Issuance of shares upon conversion of convertible notes |
|
|
932,084 |
|
|
|
94 |
|
| Balance, February 29, 2020 |
|
|
39,910,774 |
|
|
$ |
3,992 |
|
During the year ended February 28, 2021, the
Company recorded the following common stock transactions:
| (i) |
On September 23, 2020 and October 1, 2020, the Company sold 1,880,000 and 207,000 shares, respectively of its common stock at an offering price of $12.75 per share in a registered direct offering, for total gross proceeds of $26,609,250. |
| (ii) |
The company issued 190,529 shares of its common stock upon the exercise of warrants. |
| (iii) |
On October 15, 2020, the Company issued 200,000 shares of common stock to settle restricted stock units related to the President and Chief Executive Officer. |
| (iv) |
The Company issued 25,388 shares of its common stock to settle restricted stock units that vested in the period. |
During the year ended February 29, 2020, the
Company recorded the following common stock transactions:
| (i) |
On March 1, 2019, the Company sold 600,000 shares of its common stock at an offering price of $8.55 per share in a registered direct offering, for gross proceeds of $5,130,000; |
| (ii) |
On March 8, 2019 and March 11, 2019, the Company issued 150,000 shares of its common stock in settlement of a legal matter; |
| (iii) |
On April 9, 2019, the Company converted convertible notes with a face value of $2,650,000 plus accrued interest of $80,241 at a conversion price of $8.55, into 319,326 common shares; |
| (iv) |
On June 14, 2019, the Company sold 4,093,567 shares of its common stock at an offering price of $8.55 per share in a registered direct offering, for gross proceeds of $35,000,000; |
| (v) |
On July 17, 2019, the Company issued 15,432 shares of common stock upon the exercise of warrants; |
| (vi) |
On January 16, 2020 and January 21, 2020, the Company converted convertible notes with a face value of $4,900,000 at a conversion price of $8.10 plus $80,000 of accrued interest at a conversion price of $10.23 into a total of 612,758 shares of common stock; |
| (vii) |
The Company issued 244,884 shares of common stock, in aggregate, upon the vesting of restricted stock units related to employees and directors; and |
| (viii) |
The Company issued 69,101 shares of common stock, in aggregate, upon the cashless exercise of stock options related to employees; |
|